Enhanced Recovery After Surgery (ERAS) programs have reduced hospital length of stay (LOS) and complications in studies conducted at or near sea level. The authors hypothesize that chronic hypoxia and population-specific genetic adaptations at high altitude alter baseline physiology and therefore may change how ERAS components affect perioperative outcomes. The PAERS (Plateau Adaptation–ERAS Remodeling Syndrome) hypothesis was developed to conceptualize these altitude-specific shifts and to propose an altitude-aware risk stratification framework.
The study analyzed a retrospective cohort of 612 adults who underwent elective laparoscopic cholecystectomy at Qinghai Red Cross Hospital, located at an altitude of 2260 m, between 2018 and 2023. The manuscript is a preprint and has not been peer reviewed. The authors report institutional ethics approval (Ethics Committee of Qinghai Red Cross Hospital, Approval No.: LW2026-73) and state that data are available on reasonable request.
Three analytical tiers were applied to evaluate how ERAS effects are remodeled at high altitude:
Multivariable regression comparing risk factor coefficients derived from the plateau cohort against established plain-altitude benchmarks to detect weight remodeling of predictors.
Restricted cubic spline modeling and interaction analyses focused on hemoglobin (Hb), peripheral oxygen saturation (SpO2), and LOS to identify non-linear relationships and effect modification.
An inferential, population-level genetic modifier analysis using reported carrier rates of EPAS1 (encoding HIF-2α) to examine whether a high prevalence of altitude-adaptive alleles could act as baseline modifiers of ERAS effects.
Primary outcomes defined by the authors were length of stay (LOS) and overall complication rate after elective laparoscopic cholecystectomy.
The investigators targeted LOS and postoperative complications as primary endpoints to quantify changes in ERAS performance at altitude. Specific numerical outcomes for complication rates in the cohort beyond the high-level statements were not detailed in the abstract; the source reports comparative effect sizes and interaction coefficients relevant to LOS and risk-factor weights.
Three main dimensions of plateau ERAS remodeling were reported:
Weight Remodeling: In the plateau cohort BMI replaced sex as the primary risk factor for the outcomes assessed (reported odds ratio 1.86, P < .001). Surgeon-related variability was substantially larger than referenced plain-altitude benchmarks (reported F = 6.33 compared with benchmark F-statistics of 2–4), with the authors noting an approximately 58% increase in the F-statistic ratio (P < .001).
Marker Failure: Hemoglobin demonstrated a non-linear, J-shaped association with LOS. The authors report a statistically significant interaction between Hb and SpO2 (interaction beta = -0.0095, P = .009), and describe an effect reversal of Hb across different SpO2 strata—summarized by the authors as a "Plateau Hemoglobin Paradox." This suggests conventional biomarkers and their expected directional effects may not apply uniformly at altitude.
Genetic Modification: Using published population-level carrier rates, the authors infer a high prevalence of EPAS1 altitude-adaptive alleles in the study population (reported median ~70%, range 57–85% across studies). They propose that constitutive differences in the HIF-2α pathway represent a baseline modifier that should be accounted for when applying ERAS elements at high altitude.
Based on findings, the authors propose the PAERS framework to integrate altitude-aware considerations into ERAS risk stratification. PAERS emphasizes three domains clinicians and researchers should consider when adapting ERAS protocols for plateau settings: (1) reassessment of predictor weights, (2) validation of biomarker performance and thresholds, and (3) incorporation of population genetic background as a potential modifier of physiological set points and treatment response.
The authors present three falsifiable predictions as part of the PAERS hypothesis (the abstract indicates three predictions but does not list their precise wording in full). These predictions are intended to be tested in future work to validate whether (a) risk-factor hierarchies shift reproducibly at altitude, (b) common biomarkers such as Hb and SpO2 show consistent non-linear interactions affecting LOS and complications, and (c) accounting for altitude-adaptive genetic variation (for example, EPAS1 carrier status at the individual or population level) materially improves risk stratification and ERAS tailoring.
Key limitations inherent in the reported work include its retrospective design and reliance on population-level genetic inferences rather than individual genotyping within the cohort. The manuscript is a preprint and the authors explicitly note it has not been peer reviewed; they caution it should not be used to guide clinical practice. Ethical approval was provided by the Qinghai Red Cross Hospital Ethics Committee (Approval No.: LW2026-73). The authors state that all data produced are available upon reasonable request.
The authors conclude that ERAS protocols validated at sea level may undergo three main challenges at high altitude: effect weight remodeling, biomarker failure, and genetic background calibration. They argue for moving from a one-size-fits-all ERAS approach to an altitude-aware, patient-specific protocol, operationalized by the PAERS risk stratification model. The preprint frames these conclusions as hypothesis-generating and proposes targeted tests to validate the model in future, prospectively designed studies.
Note: All statements, effect sizes, and statistical values in this rewrite are taken directly from the source preprint abstract and associated information provided in the source. The work described is a preprint and has not been peer reviewed; further methodological and numerical details beyond those reported in the source were not available in the abstract.